Sources 1 Clinical Trials Arena, 2024 was a record year for obesity trials and 2025 is already poised to take over
Comprehensive review on alzheimers disease: Causes and treatment
The FDA approved this drug for use in weight management in Research from 2023 has found that people taking Wegovy lost more weight than those taking a placebo, with a mean difference in total weight loss of Zepbound Zepbound received FDA approval for use in weight management in Saxenda Saxenda received While Saxenda is effective for weight loss, people may notice slower or less obvious results
The FDA's announcement that the shortage was resolved means compounding of semaglutide will no longer be permitted under current regulations
As interest in GLP-1 therapy continues to grow, many conversations focus less on the medications themselves and more on everyday realities such as GLP-1 cost, GLP-1 side effects, and GLP-1 accessibility
Some of the most compelling research: One study, published in July 2026 in BMJ Open , compared the effects of GLP-1s with approved AUD drugs
